ArticleBMC chemistry2026
Design, synthesis, and biological evaluation of pyridylamide-type neonicotinoid derivatives based on flupyrimin scaffold.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The sucking pests such as aphids, planthoppers, and whiteflies pose a significant threat to global crop productivity, causing estimated losses of up to 40% in affected areas. Reports indicate that resistance to traditional agents such as imidacloprid has increased by more than 50% over the last decade, underscoring the urgency for innovative solutions. Neonicotinoids, which target insect nicotinic acetylcholine receptors (nAChRs), remain a vital component of pest management, offering an important alternative. Flupyrimin, a pyridylamide-type neonicotinoid with a unique mode of action on insect nAChRs, exhibits strong efficacy against resistant pest populations. In this study, a synthetic route to Flupyrimin was established, and the design and preparation of ten structural analogs were carried out. In these analogs, the trifluoroacetyl group was replaced by pyridylcarbamoyl moieties, and the pyridine ring was further derivatized. The synthetic strategy utilizes mild, non-hazardous solvents and high-efficiency reaction conditions, thus providing a practical and scalable approach for the generation of this novel class of compounds. Bioassays against Lipaphis erysimi (200 mg/L) demonstrated that compounds IIIa and IIIc exhibited mortality rates in excess of 45%, while IIIb exhibited a mortality rate that exceeded 65% mortality. Molecular docking simulation indicated that IIIb exhibited the strongest binding to insect nAChRs, supported by favorable hydrogen-bonding and π-π interactions. Conversely, fluorine substitution at the 3-position in IIIc resulted in a slight deviation in binding orientation and a reduction in affinity. Furthermore, the larger chlorine atom in IIId introduced steric hindrance that prevented optimal binding. Single-crystal X-ray analysis of IIIe confirmed its structure and conformation. These results suggest that pyridylamide-based neonicotinoids may serve as a valuable scaffold for the development of next-generation insecticidal agents. The distinct structural features of these receptors are distinct, and their predicted binding modes suggest the potential for different receptor interactions. This has the potential to provide avenues for future resistance-management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.